Stem cell therapy for heart failure reduced major CV events and death, not hospitalization
- Adults with chronic, class II or III heart failure with reduced ejection fraction (HFrEF), as defined by the New York Heart Association criteria, who were treated with stem cells experienced a 65% reduction in non-fatal heart attack or stroke events.
- In NYHA class II heart failure (HF) patients with high levels of inflammation, heart attack and stroke numbers dropped 79% after stem cell treatment.
- Stem cell treatment reduced death related to cardiovascular issues by 80% among adults with high levels of inflammation and less damaged hearts (class II heart failure).
- There was no reduction in hospitalizations for heart failure events among adults with heart failure who received a stem cell treatment.
Embargoed until 3:45 p.m. CT/4:45 p.m. ET, Sunday, Nov. 14, 2021
(NewMediaWire) - November 14, 2021 - DALLAS - Stem cell therapy helped to reduce the number of heart attacks, strokes and death among people with chronic, high-risk, NYHA class II or III heart failure with reduced ejection fraction (HFrEF), especially among those who have higher levels of inflammation, yet hospitalization was not reduced, according to late-breaking research presented today at the American Heart Association’s Scientific Sessions 2021. The meeting is fully virtual, Saturday, November 13-Monday, November 15, 2021, and is a premier global exchange of the latest scientific advancements, research and evidence-based clinical practice updates in cardiovascular science for health care worldwide.
Heart failure is a condition when the heart is unable to adequately pump blood to meet the body’s need for oxygen and nutrients. In heart failure with reduced ejection fraction (HFrEF), the heart muscle enlarges and weakens, resulting in a decrease in pumping ability and fluid buildup in the body’s tissues. Inflammation plays a significant role in the progression of heart failure over time.
This study set out to examine the effects of using stem cells (mesenchymal precursor cells) injected into the heart to target inflammation and treat chronic heart failure. Researchers hypothesized that a single injection of stem cells from healthy adult donors in addition to guideline-directed medical therapy (GDMT) for heart failure would affect the number of times participants were hospitalized for heart failure events and reduce heart attacks, strokes, and/or death.
“Cell therapy has the potential to change how we treat heart failure,” says Emerson C. Perin, M.D., Ph.D., the study’s lead author, the director of the Center for Clinical Research and medical director of the Texas Heart Institute in Houston. “This study addresses the inflammatory aspects of heart failure, which go mostly untreated, despite significant pharmaceutical and device therapy development. Our findings indicate stem cell therapy may be considered for use in addition to standard guideline therapies.”
The “Randomized Trial of Targeted Transendocardial Delivery of Mesenchymal Precursor Cells in High-Risk Chronic Heart Failure Patients with Reduced Ejection Fraction” study also called the DREAM-HF trial, is the largest stem cell therapy study to date among people with heart failure. In this multi-center, randomized, sham-controlled, double-blind trial, researchers enrolled 537 participants (average age 63, 20% female) with heart failure and reduced ejection fraction, which is when the left side of the heart, its main pumping chamber, is significantly weakened.
Heart failure was defined using the New York Heart Association (NYHA) functional classification system. This classification system places patients in one of four categories based on how much they are limited during physical activity. Class I heart failure means no limitation of physical activity, with class IV heart failure meaning an inability to have any physical activity without discomfort.
Participants were randomly divided into two groups: 261 adults received an injection of 150 million mesenchymal precursor cells, commonly known as stem cells, directly into the heart using a catheter. The remaining 276 adults received a scripted, or sham, procedure. Healthy adult donors provided the mesenchymal precursor cells.
The study participants were discharged from the hospital the day after the procedure, and researchers followed these participants for an average of 30 months. The study’s focus was to examine if the stem cell treatment affected the likelihood of participants returning to the hospital for treatment of worsening heart failure. They also tracked whether participants had a heart attack or stroke, or died, and measured levels of high-sensitivity C-reactive protein (CRP), a measure in the blood indicating inflammation.
While researchers did not see a decrease in hospitalizations due to the stem cell treatment, they did notice several other significant results. The findings include:
- Those who received stem cell therapy had a 65% reduction in non-fatal heart attacks and stroke throughout the period of the study;
- Participants with high levels of inflammation (CRP levels of at least 2 mg/L) were 79% less likely to have non-fatal heart attack or stroke after being treated with stem cells; and,
- Stem cell treatment reduced cardiac death by 80% in people with high levels of inflammation and less severe, class II HF.
“We were impressed to learn that stem cell treatment effects were additive to current standard heart failure treatments,” says Perin. “For the first time, the known anti-inflammatory mechanism of action of these cells may be linked to a cause-and-effect benefit in heart failure. The stem cells acted locally in the heart, and they also helped in blood vessels throughout the body.”
Perin and colleagues believe further research is needed to better understand how these stem cells may affect the course of progression of heart failure and how these therapies may be directed to the patient groups that could see the most benefits.
Limitations to the research include the selection of endpoints commonly used in heart failure studies. The study’s results suggest that traditional endpoints associated with recurrent heart failure hospitalization do not fully reveal the benefits or mechanisms of these stem cells on heart attack, stroke and death in patients with chronic heart failure.
Co-authors are Barry H. Greenberg, M.D.; Kenneth M. Borow, M.D.; Timothy D. Henry II, M.D.; Farrell O. Mendelsohn, M.D.; Les R. Miller, M.D.; Elizabeth Swiggum, M.D.; Eric D. Adler, M.D.; Christopher A. James, P.A.; and Silviu Itescu, M.D. Authors’ disclosures are listed in the abstract.
The study was funded by Mesoblast, Inc.
- Multimedia is available on the right column of the release link https://newsroom.heart.org/news/stem-cell-therapy-for-heart-failure-reduced-major-cv-events-and-death-not-hospitalization?preview=65a90d2e6726cc0c56f40801fb123db0
- AHA Scientific Session 2021 Online Program Planner
- Gene editing technology may improve accuracy of predicting individuals’ heart disease risk
- Induced Pluripotent Stem Cells for Cardiovascular Disease Modeling and Precision Medicine: A Scientific Statement From the American Heart Association
- For more news at AHA Scientific Sessions 2021, follow us on Twitter @HeartNews #AHA21
Statements and conclusions of studies that are presented at the American Heart Association’s scientific meetings are solely those of the study authors and do not necessarily reflect the Association’s policy or position. The Association makes no representation or guarantee as to their accuracy or reliability. The Association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific Association programs and events. The Association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and biotech companies, device manufacturers and health insurance providers and the Association’s overall financial information are available here.
The American Heart Association’s Scientific Sessions 2021 is a premier global exchange of the latest scientific advancements, research and evidence-based clinical practice updates in cardiovascular science for health care professionals worldwide. The 3-day meeting will feature more than 500 sessions focused on breakthrough cardiovascular basic, clinical and population science updates in a fully virtual experience Saturday, November 13 through Monday, November 15, 2021. Thousands of leading physicians, scientists, cardiologists, advanced practice nurses and allied health care professionals from around the world will convene virtually to participate in basic, clinical and population science presentations, discussions and curricula that can shape the future of cardiovascular science and medicine, including prevention and quality improvement. During the three-day meeting, attendees receive exclusive access to more than 4,000 original research presentations and can earn Continuing Medical Education (CME), Continuing Education (CE) or Maintenance of Certification (MOC) credits for educational sessions. Engage in Scientific Sessions 2021 on social media via #AHA21.
About the American Heart Association
The American Heart Association is a relentless force for a world of longer, healthier lives. We are dedicated to ensuring equitable health in all communities. Through collaboration with numerous organizations, and powered by millions of volunteers, we fund innovative research, advocate for the public’s health and share lifesaving resources. The Dallas-based organization has been a leading source of health information for nearly a century. Connect with us on heart.org, Facebook, Twitter or by calling 1-800-AHA-USA1.
For Media Inquiries and AHA Expert Perspective: